ALOMIDE
LOE ApproachingNDAOPHTHALMICSOLUTION/DROPS
Approved
Sep 1993
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
2/8 — Basic
Drug data last refreshed 10h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ALOMIDE (lodoxamide) is an ophthalmic solution approved in 1993 for allergic eye conditions. It is a mast cell stabilizer that prevents allergic inflammatory responses in the eye. The drug is administered as topical eye drops.
$0.064MPart D
LOE ApproachingDeclining
Mature product with minimal market presence (241 claims in 2023) approaching loss of exclusivity; expect lean commercial infrastructure.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
ALOMIDE offers limited career growth due to its LOE-approaching status and minimal market presence. Roles are primarily defensive, supporting a stable installed base rather than driving expansion or innovation.
Regional Sales ManagerMedical Science Liaison
Worked on ALOMIDE at Novartis? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.